Subcellular localization of the oncoprotein MTG8 (CDR/ETO) in neural cells

Oncogene
N SacchiAndré T Hoogeveen

Abstract

The t(8;21) translocation associated with acute myeloid leukemia (AML) disrupts two genes, the AML1 gene also known as the core binding factor A2 (CBFA2) on chromosome 21, and a gene on chromosome 8, hereafter referred to as MTG8, but also known as CDR and ETO. Extensive information is available on AML1, a member of the CBF family of transcription factors, containing a highly conserved domain, the runt box, of the Drosophila segmentation gene runt. This gene is essential for the hematopoietic development and is found disrupted in several leukemias. In contrast, the function of the MTG8 gene is poorly understood. The predicted protein sequence shows two unusual, putative zinc-fingers, three proline-rich regions, a PEST domain and several phosphorylation sites. In addition, we found a region encompassing aa 443-514 predicted to have a significant propensity to form coiled coil structures. MTG8 displays a high degree of similarity with nervy, a homeotic target gene of Drosophila, expressed in the nervous system. Human and mouse wild-type MTG8 are also highly expressed in brain relative to other tissues. For these reasons, we set out to investigate the expression and subcellular localization of the MTG8 protein in neural cells. Imm...Continue Reading

Citations

Feb 1, 2003·Gene·J Nathan DavisShari Meyers
Jan 22, 2008·BMC Molecular Biology·Rakesh Singh DhandaInge Olsson
Dec 29, 2011·Frontiers in Bioscience (Landmark Edition)·Kentson Lam, Dong-Er Zhang
Jun 19, 2004·Genomics·Stefano RossettiNicoletta Sacchi
Dec 5, 2014·Stem Cells Translational Medicine·Zou LinqingTian Meiling
Aug 10, 2021·Journal of Cellular Biochemistry·Parveen KumarManisha Yadav
Feb 21, 2004·Science·Jonathan R Terman, Alex L Kolodkin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.